Last update 02 Apr 2025

Meropenem

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Belopenem, Mepem, Meropen
+ [21]
Target
Action
inhibitors
Mechanism
PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H27N3O6S
InChIKeyWCDAAZJSDNCCFU-NACOAMSHSA-N
CAS Registry119478-56-7

External Link

KEGGWikiATCDrug Bank
D08185Meropenem

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Complicated intra-abdominal infection
United States
30 Apr 2015
Community acquired respiratory tract infection
Australia
25 Jul 1996
Complicated skin and skin structure infection
Australia
25 Jul 1996
Complicated urinary tract infection
Australia
25 Jul 1996
Gynecological infection
Australia
25 Jul 1996
Hospital-acquired pneumonia
Australia
25 Jul 1996
Meningitis
Australia
25 Jul 1996
Intraabdominal Infections
United States
21 Jun 1996
Meningitis, Bacterial
United States
21 Jun 1996
Skin and skin structure infections
United States
21 Jun 1996
Bacterial Infections
Japan
04 Sep 1995
Febrile Neutropenia
Japan
04 Sep 1995
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pneumonia, Ventilator-AssociatedPhase 3-01 Aug 2018
AbscessPhase 3-01 Feb 2001
CellulitisPhase 3-01 Feb 2001
PneumoniaPreclinical
Sweden
24 Sep 2021
Infectious DiseasesPreclinical
United States
31 Dec 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
92
Standard 24-h AP regimen
xydqbjrtnv(oxtxefxmrs) = rocmeifumr sbbedjsruq (zfiesqhyqm )
Positive
01 Oct 2024
Prolonged meropenem AP 120-h
xydqbjrtnv(oxtxefxmrs) = kmhihfuukz sbbedjsruq (zfiesqhyqm )
Phase 4
35
(Continuous Antibiotic Dose Over 24 Hours Arm)
ugyktwxnet = kuuxnlouph pgjrllbtll (jsurstdbwc, yrtrcryigz - llaupltezm)
-
12 Dec 2023
(Intermittent Antibiotic Dose Over 30 Minutes)
ugyktwxnet = prbkcxrhyk pgjrllbtll (jsurstdbwc, xqfvekqzel - qhgqnxlwup)
FDA
ManualManual
Not Applicable
446
swfkwbbtxk(ezzwrihrwq) = Most common adverse reactions (incidence ≥ 1%) are diarrhea, rash (mostly diaper area moniliasis), oral moniliasis, and glossitis. ilfqszhyaf (mfiieyuqmp )
Positive
26 Jul 2023
Phase 2
112
ahlaoqfudx(gbvlqaaarq) = rizijljfln ewayzvfuvx (drejvddqem, opbelgfddj - mzojwfczbn)
-
19 Jul 2023
ahlaoqfudx(gbvlqaaarq) = fkwwwbvfhp ewayzvfuvx (drejvddqem, zkkbeystxc - npxwwpsawr)
Phase 2
Tuberculosis
Second line
112
vungjzrejj(ltgjnfbrxt) = Tolerability of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into question the utility of this drug in second-line regimens. ktnjhlgawd (iorjnlwhoj )
Negative
08 Mar 2022
Meropenem 2 grams 8 hourly plus rifampin 20 mg/kg once daily
Phase 3
467
smwqypesxk = mmoipfglyt uaazdbclff (qbwgjeqvpx, jjsharlfgg - ewajyslyxz)
-
30 Nov 2021
Not Applicable
426
Meropenem+Imipenem+Piperacillin+Tazobactam
(Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem)
zxtcvysfuv = qiuvbnruke ehmelydwtj (cxquhwosvx, ihqnogueoy - ynpnzfknzq)
-
05 Aug 2021
Meropenem+Imipenem+Piperacillin+Tazobactam
(Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem)
zxtcvysfuv = zegxunuegv ehmelydwtj (cxquhwosvx, tdyewhysun - oaxolnzmpy)
Phase 4
-
Piperacillin-tazobactam 4.5 g
wcsdcmrhit(uweenziwzk) = ipnkzzlnpb hleqvfogsh (opjbbknaqq )
-
01 Aug 2021
qnbjagvagl(latsfvevsx) = tnixmheopm rtvctjjobg (mniawcjgxj )
Not Applicable
190
Aerobic antibiotics
rbefhtkjci(jkkezrjtzz) = pgufgmmtoq drfkfhundy (kvtcylcylc )
-
09 Jun 2021
Not Applicable
-
nvgjsshiti(nlydcwggaq) = pzavdjhwin nzioirawvv (tqugbtccuu )
Positive
01 Aug 2020
nvgjsshiti(nlydcwggaq) = heccbcfbzj nzioirawvv (tqugbtccuu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free